ARTICLE | Company News

Echo Therapeutics diagnostic news

October 6, 2014 7:00 AM UTC

Echo said that it suspended its operations to conserve liquidity and capital resources because the company believes that it has insufficient resources to fund its needs beyond Sept. 30. The suspension follows a strategic review of the company's financial position, funding alternatives and projected product development costs and timelines. Echo said that resuming operations is dependent on securing additional third-party funding. As of June 30, Echo has $4.1 million in cash and a six-month operating loss of $6.6 million. ...